Previous Close | 256.60 |
Open | 260.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 259.20 - 266.75 |
52 Week Range | 201.60 - 307.10 |
Volume | |
Avg. Volume | 7,675,152 |
Market Cap | 316.079B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 26.34 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.50 (0.58%) |
Ex-Dividend Date | Jul 07, 2023 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BIOCON.NS
U.S. drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday. The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference. Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International.
Indian biopharmaceutical company Biocon Ltd swung to a third-quarter profit on Thursday, boosted by its biosimilars business and the sale of some of its non-core units, and said Chief Financial Officer Indranil Sen had resigned. Sen, who has been with the company for nearly a decade, resigned from the role to pursue career opportunities outside of Biocon, it said. For the latest quarter, the Bengaluru-based company reported a consolidated net profit of 6.6 billion rupees ($79.6 million), compared with a loss of 418 million rupees a year earlier.
Indian biopharmaceutical company Biocon Ltd is planning to list its biosimilars business, a significant contributor to the company's total revenue, by the first half of 2025, a top executive said on Friday. "I would say it (listing of the biologics business) can happen any time after the second half of 2024 ... it is likely to happen in the first half of 2025," Biocon Ltd CEO and Managing Director Siddharth Mittal told Reuters. Last year, Biocon acquired U.S.-based Viatris Inc's biosimilar business.